OXGN $2.40 Drei Krebsmedikamente in der Pipeline!

OXGN $1.41 - Hearing a tender offer in the $3's in negotiation. eom  

Tender offer soll bei $3.88 liegen! Aktueller Kurs $1.64  

OXGN $1.61 next targets : $1.94 (MA100) & $2.48 (MA200) after that blue sky!  

Aktueller Kurs : $1.64 Tageshoch  

Im Bereich von $1.53-$1.55 hat sich ein key support ausgebildet.
Heutiger Schlusskurs liegt bei $1.59. Meiner Meinung nach werden wir nächste Woche Richtung $2+ laufen.  

 

nachbörslich kracht es gewaltig nach unten! 1 Dollar???  

OXGN and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use B...

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, and Azanta Danmark A/S, a specialty pharmaceutical company focused on oncology, women's health and addiction medicine, have established a partnership agreement to provide access to ZYBRESTAT for the treatment of patients in Europe and Canada with anaplastic thyroid cancer (ATC) on a compassionate use basis. OXiGENE's newly-formed Named Patient Program (NPP), to be managed by Azanta, provides a regulatory mechanism to allow healthcare professionals in Europe and Canada to prescribe ZYBRESTAT to individual ATC patients while it is still in development.

Under the terms of the agreement, OXiGENE will provide ZYBRESTAT to Azanta. Azanta will serve as exclusive distributor for ZYBRESTAT in the specified territory for this purpose and will provide ZYBRESTAT to physicians solely to treat ATC on a compassionate use basis in the territory covered by the agreement until such time as ZYBRESTAT may obtain marketing approval in that territory. The territory includes the European Union, including the Nordic countries and Switzerland, and Canada, and the agreement may also be expanded to include other countries on a country-by-country basis. OXiGENE and Azanta will cooperate on regulatory activities relating to ZYBRESTAT for the treatment of ATC within the territory. There will be no transfer of ownership of intellectual property rights for ZYBRESTAT to Azanta under the terms of the agreement.

Commented Peter J. Langecker, M.D., Ph.D., Chief Executive Officer of OXiGENE: "This agreement represents a critical milestone in the ongoing development of ZYBRESTAT, reflecting OXiGENE's commitment to facilitate access to this potentially valuable therapy by ATC patients who have no other treatment options. We are delighted to work in partnership with Azanta, a privately held European specialty pharmaceutical company with specialized technical and regulatory expertise in implementing compassionate use programs. While Azanta focuses on our Named Patient Program, we will continue to pursue a global regulatory strategy for ZYBRESTAT in ATC, including seeking additional financing for the FACT 2 study, with the goal of initiating this pivotal trial in 2012."

Commented Claus Moeller, Chief Executive Officer of Azanta: "Partnering with OXiGENE to distribute ZYBRESTAT to European and Canadian ATC patients under appropriate regulatory auspices reflects our strategy to build industry leadership by making innovative developmental therapies available to patients in international markets. We believe that ZYBRESTAT has generated an impressive body of safety and activity data, with a suggested survival benefit in ATC, and has significant therapeutic and commercial potential. We are pleased to make our distribution and regulatory expertise available to help advance this promising therapeutic option, and we look forward to a productive collaboration."

About ZYBRESTAT

OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

About Azanta

Azanta A/S is a specialty pharma company primarily operating within oncology, women's health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical concepts. Azanta A/S currently markets or makes available nine specialty pharma products in the Nordic region and in the U.K., including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk development projects which are planned to be commercialized within the next two to three years.

The Azanta Danmark A/S logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11229

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include possible outcomes of clinical studies involving ZYBRESTAT, interest among potential partners or regulatory filings and outcomes, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: Investor and Media Contact:
ir@oxigene.com
650-635-7000  

Einkauf heute zu $1.10 - Akite hat einen extremen Boden gebildet und könnte erst einmal das Gap bei $1.65 schließen!  

 

Mkt Cap (Mil) $15.62 bei $1.11
Shares Out (Mil) 14.88
Float (Mil) 13.04
http://www.dailyfinance.com/quote/nasdaq/...e-inc/oxgn/key-statistics
http://finance.yahoo.com/q/ks?s=OXGN+Key+Statistics  

Ausgestoppt bei $1.06 - volumen hat nachgelassen.  

 

Bruch der $1.37 wird die Aktie schnell Richtung $1.68 ( gap fill ) katapultieren!  

kommen und der Deckel fliegen. Sag nur Phase 3: http://oxigene.com/pipeline/pipeline/

 

Bin gespannt wann es hier mal richtig kracht!  

Erwartet ihr hier gute Zahlen? Hab mir nun auch mal ne kleine Posi gegönnt :P

 

geil!  

.......endlich gekracht gestern nachbörslich ca.+50 %  

 

OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting


SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.

PCV found more often in individuals of African-American and Asian descent is a disease involving abnormal blood vessels of the macula characterized by recurrent serosanguinous detachment of the retinal pigment epithelium (RPE), submacular hemorrhage and development of subretinal polyps with resulting vision loss. The FAVOR study (Fosbretabulin Against Vasculopathy of the Retina/Choroid) was a randomized, double-masked Phase 2 study conducted in 20 Asian patients at seven clinical trial sites, which compared the outcome of a single intravenous dose of ZYBRESTAT (15, 25, 35 or 45 mg/kg) with placebo. The data showed that there was a transient reduction in polyp activity seen with indocyanine green angiography (ICGA) in a patient treated with 15 mg fosbretabulin and a transient reduction in subretinal fluid seen on optical coherence tomography, or OCT, in a patient treated with 45 mg fosbretabulin. The proportion of eyes with worsened findings on OCT/ICGA was significantly higher in the placebo group (p=0.032). These data suggest that ZYBRESTAT even if administered only as a single dose intravenously may produce a transient reduction in both polyp activity and amount of subretinal fluid in patients with PCV, and that further clinical testing with a more practical topical formulation potentially in combination with photodynamic therapy (PDT), may be warranted. No drug-related serious adverse event was observed in the study.

The data were presented at the 2012 annual meeting of the American Academy of Ophthalmology, being held in Chicago, in a poster titled, "Phase 2 Clinical Trial of Intravenous Fosbretabulin in the Treatment of Polypoidal Choroidal Vasculopathy (Fosbretabulin Against Vasculopathy of the Retina/Choroid: FAVOR Study)" by Timothy Y. Y. Lai, MD, FRCS, FRCOphth , Chinese University Hong Kong, et al.

"We believe that ZYBRESTAT has potential as a treatment for PCV and other ocular diseases involving abnormal blood vessel formation, such as age-related macular degeneration, and could potentially improve upon injectable anti-angiogenic agents which are used to treat these diseases, but which may have limited efficacy," said Jai Balkissoon, MD, FACS, Vice President Clinical Development, OXiGENE.

OXiGENE has previously reported positive results from proof-of-concept Phase 2 studies using an intravenous formulation showing that ZYBRESTAT achieved the primary endpoint of stable disease in patients with myopic macular degeneration (MMD). OXiGENE has conducted preclinical studies with topical formulations of ZYBRESTAT which demonstrated attractive pharmacokinetic and safety properties and efficacy in destroying abnormal vasculature in a rat choroidal melanoma model. Data from the FAVOR study could be used to facilitate dose selection decisions for future clinical trials. OXiGENE is seeking collaborators for its ZYBRESTAT ophthalmology program, which could include future development of a topical-route ZYBRESTAT.

About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969
Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

CONTACT: Investor and Media Contact:

        ir@oxigene.com

        650-635-7000

Source: OXiGENE, Inc.


News Provided by Acquire Media